Kawasaki disease (Kawasakidiseaes), also known as muco-cuta-meouslymphnodesyndrome (MCLS), is an acute febrile exanthematous pediatric disease with systemic vasculitis as the main pathology. it was first reported by Dr. Tomisaku Kawasaki in Japan in 1967. The exact cause of Kawasaki disease is unknown, but the fulminant and epidemic nature of the disease implies that it may be infectious. Patients may have a genetic predisposition. Systemic infections result in a systemic inflammatory response, including cardiovascular, respiratory, gastrointestinal, genitourinary, neurological, and lymphatic systems. Aneurysms may form. Inflammation can also be secondary to progressive arterial stenosis. Kawasaki disease is the most common cause of acquired heart disease in developed countries. In Japan, Kawasaki disease affects 1 in 90 children under 5 years of age. In the continental United States, it affects 1 in 1000 children under 5 years of age. Asian origin, positive family history, and children under 5 years of age are the prevalent population for the disease. The typical clinical presentation is a sudden onset in children under 5 years of age with fever and 4 of 5 symptoms, including: conjunctival congestion without accumulation of corneal rims; erythema of the throat, tongue, and lips with visible peeling of the lips; a variety of rashes, most commonly in the groin with flaking; erythema and swelling of the extremities; and enlarged lymph nodes in the neck. Other nonspecific symptoms include excessive irritability, refusal to bear weight, vomiting, and diarrhea. Acute Kawasaki disease rarely results in death and is most often seen as a missed or late diagnosis. Echocardiography may reveal pericardial effusion, loss of normal tapering structure of the coronary arteries, coronary aneurysm, decreased left heart function, and mitral valve closure insufficiency. CTA has the best sensitivity and specificity for small coronary artery dilatations, aneurysms and stenoses. Treatment recommendations: All patients should receive intravenous immunoglobulin and oral high-dose aspirin as soon as possible after diagnosis. Intravenous immunoglobulin administered within the first 10 days reduces the risk of complicating coronary artery disease and improves myocardial function. In patients with existing coronary abnormalities, continued long-term use of low-dose aspirin is required. In patients with severe pre-existing coronary artery disease, clopidogrel and/or anticoagulation may be used. In refractory cases, prednisolone may be added. Most children with Kawasaki disease respond to immunoglobulin therapy, and the prognosis is better in children who have not developed coronary abnormalities 4 to 6 weeks after the onset of fever. In severe cases, there may be thrombotic coronary occlusion and myocardial infarction, which may require interventional or bypass therapy. Extremely critical patients may require heart transplantation. The above excerpt has been taken from “Clove Garden” In clinical practice, mainly for children with fever for more than 3 days, if you find that the child has a rash, conjunctival congestion, cherry red mouth and lips, dry and cracked, tongue in the shape of prunes, swollen fingers and toes, peeling skin, be alert, it is recommended to go to the hospital to check the blood picture, C-reactive protein, blood sedimentation, cardiac ultrasound to see if the coronary arteries are dilated, so that the timely detection of the disease is conducive to improve the diagnosis and timely Treatment.